Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue pharmacy policy update: Coverage & Pr…
    Ask Trek AI about this page
    ModifiedFlorida BluePolicy N/A

    Responsible Quantity Program — Pharmacy program updates (Responsible Quantity limits, step therapy, prior authorization, coverage exclusions)

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Updates to Florida Blue's pharmacy programs effective April 1, 2025, including additions to the Responsible Quantity Program (drug-specific dispensing limits) and related step therapy, prior authorization, and coverage exclusion changes for members whose plans include these programs.

    Policy Summary
    PayerFlorida Blue
    PolicyResponsible Quantity Program — Pharmacy program updates
    Policy CodePolicy N/A
    Change TypeProgram additions and authorization rule changes
    Effective DateApr 1, 2025
    Last ReviewApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit Net Results authorization requests via MyPrime.com using the Florida Blue Net Results Formulary form.
    SourceLink
    POLICY UPDATE CHANGES

    Multiple drugs and specific dispensing limits were added to the Responsible Quantity Program effective April 1, 2025.

    Certain drugs were added to Step Therapy and Net Results Step Therapy programs (e.g., Aclometasone dipropionate 0.05% ointment and Emrosi 40 mg).

    New pharmacy coverage exclusions and Net Results formulary exclusions were listed effective April 1, 2025.

    Prior authorization requirements were changed for numerous medications for members in the Prior Authorization Program effective April 1, 2025.

    Apr 1, 2025implementation date

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >20drugs with specified limits
    Dozensdrugs listed with limits
    Net Resultsseparate formulary
    MyPrime.comauthorization forms

    Coverage Criteria Summary

    Effective April 1, 2025, Florida Blue's commercial pharmacy plans and the Net Results formulary will implement new pharmacy coverage exclusions. For members enrolled in plans that permit pharmacy coverage exclusions, the payer will no longer cover the specific brand‑name and generic drugs listed in the Responsible Quantity Program exclusion lists; therapeutic or generic alternatives may still be covered. This exclusion for Net Results applies to the separate Net Results formulary and is effective April 1, 2025.

    These exclusions apply only to members whose health plans allow pharmacy coverage exclusions; providers should verify member eligibility and benefit design before prescribing or dispensing affected products. Examples from the lists include ophthalmic clobetasol formulations and other named products; the full exclusion lists are published in the Responsible Quantity Program materials effective April 1, 2025.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior authorization required for listed drugs

    Prior authorization is required for the long list of medications identified in the policy for members whose plans are part of the Prior Authorization Program, effective April 1, 2025. Submitting a prior authorization is necessary before dispensing these drugs for covered indications for affected members.

    • Applies only to members whose plans are part of the Prior Authorization Program.
    • Effective April 1, 2025 for the listed medications.
    Prior Authorization

    Net Results authorization submissions must use MyPrime.com forms

    Net Results authorization requests must be submitted using the Florida Blue Net Results Formulary authorization forms on MyPrime.com; use the Net Results authorization request process when requesting authorization for Net Results-covered medications.

    • Use the Florida Blue Net Results Formulary authorization forms available on MyPrime.com.
    • Complete and submit the Net Results authorization request form for the drug and indication being requested.
    Step Therapy

    Step therapy program updates and retirements

    Step therapy program entries were updated: Emrosi 40 mg capsules were added to oral tetracycline step therapy and Aclometasone dipropionate 0.05% ointment was added to topical corticosteroid step therapy; the Xdemvy step therapy program was retired. Net Results also added Zituvimet and Zituvimet XR to the DPP‑4 inhibitors and combinations program.

    • Oral tetracycline step therapy: Emrosi 40 mg added.
    • Topical corticosteroid step therapy: Aclometasone dipropionate 0.05% ointment added.
    • Xdemvy step therapy: program retired.
    • Net Results Step Therapy: Zituvimet and Zituvimet XR added to DPP‑4 inhibitors and combinations.
    Note

    Provider actions required for members in affected programs

    Providers must follow the updated authorization, step therapy, and quantity limit procedures described in this policy when treating members enrolled in the Responsible Quantity, Prior Authorization, or Net Results programs.

    • Verify which pharmacy program(s) apply to the member before prescribing or dispensing.
    • Submit required Net Results authorization forms via MyPrime.com when applicable.
    • Adhere to step therapy requirements and quantity limits effective April 1, 2025.
    Documentation Required

    How to obtain Net Results authorization forms on MyPrime.com

    To obtain Net Results authorization request forms, go to MyPrime.com, create a profile or click Forms and select Continue without signing in, then proceed to the Florida Blue Net Results Formulary forms.

    • Create a MyPrime.com profile OR: Forms > Continue without signing in.
    • Select Florida Blue from the top dropdown and answer No to Medicare status when prompted before accessing Forms.
    • On the next page click Forms, then select Florida Blue Net Results Formulary to view forms.
    Documentation Required

    Access Florida Blue Net Results authorization forms (select Florida Blue)

    Use the Florida Blue Net Results Formulary authorization request forms on MyPrime.com: select Florida Blue from the top dropdown, answer No to the Medicare status question, then choose the Florida Blue Net Results Formulary form category to access authorization forms.

    • Select Florida Blue from the top dropdown menu and No to the Medicare status question.
    • On the following page click Forms, then select Florida Blue Net Results Formulary to view available form categories.
    Denial Risk

    Claims may be denied without required prior authorization

    Claims for the medications listed under 'Medications Requiring Prior Authorization' may be denied if a required prior authorization is not obtained for members in the Prior Authorization Program.

    • Denials apply only to members whose plans are part of the Prior Authorization Program.
    • Obtain and document required prior authorization before dispensing to avoid claim denial.
    Denial Risk

    Potential denial or authorization required for quantity limit exceedance

    Requests that exceed the Net Results quantity limits listed in the Net Results Quantity Limit Program (effective April 1, 2025) may be denied or require authorization per the Net Results quantity limit program.

    • Quantity limits and the specific limits (e.g., Attruby 112 tabs/28 days; Tramadol 75 mg 150 tabs/30 days; Revuforj 110 mg 120 tabs) are listed in the Net Results Quantity Limit Program.
    • If prescribing above the listed limit, submit an authorization request per Net Results procedures to avoid denial.

    Step Therapy Program Details

    ProgramChange / Drug addedNotes
    {"text":"Oral tetracycline step therapy","status":""},{"text":"Emrosi 40 mg capsules added to program","status":""},{"text":"Applies to members in the Responsible Quantity Program; effective Apr 1, 2025","status":""}
    {"text":"Topical Corticosteroid step therapy","status":""},{"text":"Aclometasone dipropionate 0.05% ointment added to program","status":""},{"text":"Applies to members in the Responsible Quantity Program; effective Apr 1, 2025","status":""}
    {"text":"Xdemvy Step therapy","status":""},{"text":"Program retired","status":""},{"text":"Removal from program effective Apr 1, 2025","status":""}
    {"text":"Net Results DPP-4 Inhibitors and Combinations (Net Results Step Therapy)","status":""},{"text":"Zituvimet and Zituvimet XR added","status":""},{"text":"Applies to Net Results formulary; effective Apr 1, 2025","status":""}

    Responsible Quantity Program — Drug-Specific Dispensing Limits

    Multiple (see list)
    OverviewMultiple drugs in the Responsible Quantity Program and Net Results Quantity Limit Program have specific dispensing limits effective Apr 1, 2025; limits apply to members whose plans include the respective program.
    Examples included belowDrug-specific monthly or 28-day dispensing limits are defined per drug (tables, pens, vials, capsules, grams, kits) — see individual entries for exact limits.
    Program applicabilityResponsible Quantity Program limits apply to members in that program; Net Results limits apply to the Net Results formulary as noted, both effective Apr 1, 2025.
    Attruby
    DrugAttruby
    Quantity limit112 tablets per 28 days (Net Results)
    Policy Summary
    PayerFlorida Blue
    PolicyResponsible Quantity Program — Pharmacy program updates
    Policy CodePolicy N/A
    Change TypeProgram additions and authorization rule changes
    Effective DateApr 1, 2025
    Last ReviewApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit Net Results authorization requests via MyPrime.com using the Florida Blue Net Results Formulary form.
    SourceLink
    On This Page
    Coverage Criteria SummaryProvider Actions and Authorization RequirementsStep Therapy Program DetailsResponsible Quantity Program — Drug-Specific Dispensing Limits
    Effective dateEffective Apr 1, 2025
    Benlysta
    DrugBenlysta
    Quantity limit4 pens or syringes per 28 days (Net Results)
    Effective dateEffective Apr 1, 2025
    Danziten
    DrugDanziten
    Quantity limit112 tablets per 28 days (Net Results)
    Effective dateEffective Apr 1, 2025
    Ebglyss
    DrugEbglyss
    Quantity limit1 pen per 28 days (Net Results)
    Effective dateEffective Apr 1, 2025
    Edaravone
    DrugEdaravone
    Quantity limit10 vials per 28 days (Net Results)
    Effective dateEffective Apr 1, 2025
    Nemluvio
    DrugNemluvio
    Quantity limit2 pens per 28 days (Net Results)
    Effective dateEffective Apr 1, 2025
    Revuforj 110 mg
    DrugRevuforj 110 mg
    Quantity limit120 tablets per month / 30-day supply (Responsible Quantity Program) and listed as 120 tabs in Net Results
    Effective dateEffective Apr 1, 2025
    Revuforj 160 mg
    DrugRevuforj 160 mg
    Quantity limit60 tablets per month / 30-day supply (Responsible Quantity Program) and listed as 60 tabs in Net Results
    Effective dateEffective Apr 1, 2025
    Sohonos 1 mg
    DrugSohonos 1 mg
    Quantity limit120 capsules per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Sohonos 1.5 mg
    DrugSohonos 1.5 mg
    Quantity limit120 capsules per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Sohonos 2.5 mg
    DrugSohonos 2.5 mg
    Quantity limit150 capsules per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Sohonos 5 mg
    DrugSohonos 5 mg
    Quantity limit90 capsules per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Sohonos 10 mg
    DrugSohonos 10 mg
    Quantity limit60 capsules per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Tramadol 75 mg
    DrugTramadol 75 mg
    Quantity limit150 tablets per month / 30-day supply (Responsible Quantity Program) and listed as 150 tabs in Net Results
    Effective dateEffective Apr 1, 2025
    Zituvimet (non-XR)
    DrugZituvimet (non-XR)
    Quantity limit60 tablets per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Zituvimet XR 100 mg/1000 mg
    DrugZituvimet XR 100 mg/1000 mg
    Quantity limit30 tablets per 30-day supply (Net Results)
    Effective dateEffective Apr 1, 2025
    Zituvimet XR 50 mg/1000 mg
    DrugZituvimet XR 50 mg/1000 mg
    Quantity limit30 tablets per 30-day supply (Net Results) — text also references 50 mg/500 mg 60 tabs in source
    Effective dateEffective Apr 1, 2025